Anti-(+)—methamphetamine monoclonal antibodies
View Patent ↗The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.
1. An isolated antibody, wherein the antibody specifically binds (+) methamphetamine and comprises:
(a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5;
(b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:6;
(c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 7;
(d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 8;
(e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 9; and
(f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:10.
2. The isolated antibody of claim 1 , wherein the antibody is encoded by a nucleic acid sequence comprising a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.
3. The isolated antibody of claim 1 , wherein the antibody is selected from the group consisting of a single-chain antibody, an immunologically effective antibody fragment thereof, a chimeric antibody, and a humanized antibody.
4. A method for treating at least one medical problem associated with methamphetamine use in a subject which comprises administering an effective amount of the antibody of claim 1 to the subject to treat at least one medical problem.
5. The method of claim 4 , wherein the treating includes attenuating, reversing, or improving at least one symptom or sign of methamphetamine use in a subject.
6. The method of claim 4 , wherein the medical problem associated with methamphetamine use is selected from the group consisting of methamphetamine addiction and methamphetamine abuse.
7. The method of claim 4 , wherein the medical problem associated with methamphetamine use is selected from the group consisting of acute methamphetamine overdose, chronic methamphetamine overdose, and methamphetamine-use relapse.
8. The method of claim 4 , wherein the anti-(+) methamphetamine antibody binds an epitope within (+) methamphetamine, a metabolite of (+) methamphetamine, or (+) methamphetamine-like analog.
9. The method of claim 4 , wherein the antibody slows the rate of (+) methamphetamine entry into the brain of a subject.
10. The method of claim 4 , wherein the antibody reduces the frequency of methamphetamine use relapse in a subject addicted to methamphetamine.
11. An isolated bispecific antibody, wherein the antibody specifically binds at least (+) methamphetamine and comprises:
(a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5;
(b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:6;
(c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 7;
(d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 8;
(e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 9; and
(f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:10.